Secondary Logo

Journal Logo

You can read the full text of this article if you:

Ovid Member Institutional Access
Original Articles

Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study

Pagano, Tiziana MD1; De Rosa, Pasquale MD1; Vallone, Roberta MD1; Schettini, Francesco MD2; Arpino, Grazia MD, PhD2; Giuliano, Mario MD, PhD2; Lauria, Rossella MD2; De Santo, Irene MD2; Conforti, Alessandro MD, PhD1; Gallo, Alessandra MD1; Nazzaro, Giovanni MD, PhD1; De Placido, Sabino MD, PhD2; Locci, Mariavittoria MD1; De Placido, Giuseppe MD1

Author Information
doi: 10.1097/GME.0000000000001053

Abstract

Erratum

In the article appearing in volume 25, pages 657-662, titled “Fractional microablative CO 2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study” there is an error.

On page 658, left-hand column, last paragraph, first sentence is incorrect. The correct text is as follows:

In December 2014, the Federal Drug Administration cleared the fractional microablative CO 2 laser for the indications of incision, excision, ablation, vaporization and coagulation of body soft tissues in medical specialties (including gynecology and genitourinary surgery) and therefore may be used to treat vaginal itching and dryness, pain during sexual intercourse, and vaginal laxity.

Menopause. 25(10):1169, October 2018.

© 2017 by The North American Menopause Society